文献速递临床试验与 GCP流行病学与生物统计

日本汉方药预防COVID-19的多中心随机对照试验方案摘要

A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study).
PubMed 文献 · Trials · 2021-01-06

本研究为多中心、干预性、平行组、1:1随机、研究者发起的双臂试验,计划从7所日本大学医院招募6000名健康医务人员,评估汉方药补中益气汤(HET)对COVID-19症状的预防效果。主要结局为12周研究期间PCR确诊SARS-CoV-2阳性且至少有一种症状的患者数,安慰剂组与HET组各3000例。

要点

  • 补中益气汤组每日2次每次9片,安慰剂组同剂量,疗程8周,随访12周。
  • 主要结局为PCR阳性且伴发热、咳嗽、咳痰、乏力或气短中至少一种症状的患者数。
  • 计划入组6000例,α=0.05、把握度80%,采用Peto法,含9次中期分析与最终分析。

核心结论

  • 旨在验证补中益气汤对COVID-19症状具有预防作用的假设。

研究设计与样本

  • 多中心、干预性、平行组、1:1随机、研究者发起的双臂研究。
  • 从7所日本大学医院招募6000名健康医务人员,年龄20至75岁。

主要发现

  • 主要结局为12周研究期间PCR确诊SARS-CoV-2阳性且至少有一种症状(发热、咳嗽、咳痰、乏力、气短)的患者数。
  • 次要结局包括感染至发病时间、症状出现至PCR转阴时间、症状出现或改善天数、住院及ICU管理需求。

关键数值与推荐

  • 补中益气汤组每日2次每次9片,安慰剂组同剂量,疗程8周。
  • 按年龄(是否低于50岁)和COVID-19危险因素史(心血管病、高血压、糖尿病、呼吸系统疾病)进行最小化随机平衡。
  • 样本量按安慰剂组发生率2%、研究药物组1%计算,最终分析需4986例,设脱漏率16.9%,总样本6000例。

临床怎么用

  • 若试验证实有效,补中益气汤或可作为医务人员等高风险人群的COVID-19预防选择。

局限性

  • 仅对参与者设盲,安慰剂味道与补中益气汤不同。
  • 主要结局依赖PCR检测和症状报告,可能受检测可及性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: We aimed to test our hypothesis that traditional Japanese (Kampo) medicine, hochuekkito (Hochu-ekki-to: HET) has a preventive effect for the symptoms on COVID-19. TRIAL DESIGN: The study is designed as a multi-center, interventional, parallel-group, randomized (1:1 ratio), investigator sponsored, two-arm study. PARTICIPANTS: Six thousand participants will be recruited from healthy hospital workers in 7 Japanese University Hospitals. INCLUSION CRITERIA: 1. Age from 20 to 75 years old at the time of registration 2. Asymptomatic and body temperature below 37°C at the time of registration 3. Capable of eating orally Exclusion criteria: 1. Previous upper respiratory inflammation due to viral infection (including suspected COVID-19) 2. Taking immunosuppressants 3. Allergic to the Kampo medicines used in this study 4. History of hypokalaemia, severe hypertension, severe liver dysfunction, and interstitial pneumonia 5. Regularly taking other Kampo medicines 6. Pregnant or possibly pregnant 7. Participating in other research 8. Judged to be unsuitable for this study by the doctor in charge INTERVENTION AND COMPARATOR: Kampo group: participants receive HET in 9 tablets 2 times per day for 8 weeks. CONTROL GROUP: participants receive placebo in the same dosage as the Intervention group - 9 tablets 2 times per day for 8 weeks. Placebo tablets are identical in appearance and package to HET. Taste of placebo is different from that of HET. The Ohsugi Pharmaceutical Co. Ltd, Osaka, Japan manufactured the placebo and HET. MAIN OUTCOMES: Primary outcome: Number of patients with a SARS-CoV-2 RNA by ploymerase chain reaction (PCR) positive result with at least one symptom (fever, cough, sputum, malaise, shortness of breath) during the 12-week study period (including the 4-week observation period after oral administration). SECONDARY OUTCOMES: 1. Period from infection to onset 2. Period from the appearance of symptoms to the disappearance of PCR positive 3. Number of days until the appearance or improvement of symptoms 4. Severe stage: presence of hospitalization 5. Shock stage: ICU management required for mechanical ventilation, shock vitals or failure of organ(s) other than lungs Safety endpoints include numbness in the hands and/or feet, edema, skin rash or other allergic symptoms, and gastric discomfort. RANDOMISATION: Patients are randomized (1:1 ratio) to each group using minimization implemented with the Electric data capture system (DATATRAK Enterprise Cloud), with balancing of the arms with age range (under 50 years of age or not) and having a history of risk factors for COVID-19 (cardiovascular disease, hypertension, diabetes, respiratory diseases). BLINDING (MASKING): Only participants will be randomized. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): The main research hypothesis of this study is that Kampo medicines significantly prevent the onset of COVID-19. It is assumed that the infection rate before the administration of the drug under consideration will be 0% and that the incidence of COVID-19 thereafter will be 2- 3%, of which 70%-80% will show symptoms of COVID-19. Assuming that the pharmaceutical effect of the drug will be effective in 50% of patients and that the incidence rates in the placebo and drug groups will be 1.4%-2.4% and 0.7%-1.2%, respectively, the placebo is calculated at 2%, and the study drug at 1%. Since the frequency of verification is low and the number of cases will be large, we set a total of 10 analyses (9 interim analyses and a final analysis). Since the number of cases at the time of the final analysis will be 4,986 under the conditions of α = 0.05 and a power of 80% by the Peto method. We set at 600 cases in each interim analysis with an estimated dropout rate of 16.9%. Finally, the total number of cases is set to 6,000 with 3,000 in the placebo group and 3,000 in the HET group. TRIAL STATUS: Protocol version 1.3 of October 23rd , 2020. Recruitment start (expected): December 1st, 2020. Recruitment finish (expected): December 31st, 2022. TRIAL REGISTRATION: This trial is registered in the Japan Registry of Clinical Trials (jRCT) ( jRCTs031200150 ) on 14 October 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Namiki T, Takayama S, Arita R, et al. A structured summary of a study protocol for a multi-center, randomized controlled trial (RCT) of COVID-19 prevention with Kampo medicines (Integrative Management in Japan for Epidemic Disease by prophylactic study: IMJEDI P1 study). Trials. 2021. PMID: 33407828. doi:10.1186/s13063-020-04939-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。